MA45378A - Compositions comprenant du timolol et leur utilisation dans le traitement de la rosacée par administration topique - Google Patents

Compositions comprenant du timolol et leur utilisation dans le traitement de la rosacée par administration topique

Info

Publication number
MA45378A
MA45378A MA045378A MA45378A MA45378A MA 45378 A MA45378 A MA 45378A MA 045378 A MA045378 A MA 045378A MA 45378 A MA45378 A MA 45378A MA 45378 A MA45378 A MA 45378A
Authority
MA
Morocco
Prior art keywords
rosacea
treatment
topical administration
compositions including
including timolol
Prior art date
Application number
MA045378A
Other languages
English (en)
Inventor
Sanchez Maria Victoria Revilla
Encuentra Gema Tarrason
Juan Bernat Vidal
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of MA45378A publication Critical patent/MA45378A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA045378A 2016-06-16 2017-06-15 Compositions comprenant du timolol et leur utilisation dans le traitement de la rosacée par administration topique MA45378A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16382278 2016-06-16

Publications (1)

Publication Number Publication Date
MA45378A true MA45378A (fr) 2019-04-24

Family

ID=56203291

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045378A MA45378A (fr) 2016-06-16 2017-06-15 Compositions comprenant du timolol et leur utilisation dans le traitement de la rosacée par administration topique

Country Status (14)

Country Link
US (1) US20210220368A1 (fr)
EP (1) EP3471731A1 (fr)
JP (1) JP2019518039A (fr)
KR (1) KR20190017801A (fr)
CN (1) CN109475561A (fr)
AR (1) AR108792A1 (fr)
AU (1) AU2017285256A1 (fr)
BR (1) BR112018076014A2 (fr)
CA (1) CA3026974A1 (fr)
EA (1) EA201990041A1 (fr)
MA (1) MA45378A (fr)
MX (1) MX2018015240A (fr)
TW (1) TW201803568A (fr)
WO (1) WO2017216307A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115844897B (zh) * 2022-08-01 2024-07-16 北京梅尔森医药技术开发有限公司 一种治疗敏感肌肤的外用制剂及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2866567A1 (fr) * 2004-02-20 2005-08-26 Galderma Res & Dev Utilisation d'un antagoniste du recepteur beta-adrenergique, at1, 5-ht2, 5-ht5 et/ou de la galanine, pour le traitement de la rosacee
AU2006269944A1 (en) * 2005-07-19 2007-01-25 Inverseon, Inc. Improved pharmacokinetic profile of beta-adrenergic inverse agonists for the treatment of pulmonary airway diseases
FR2961695B1 (fr) 2010-06-29 2012-07-06 Galderma Res & Dev Utilisation de composes dans le traitement ou la prevention de troubles cutanes

Also Published As

Publication number Publication date
US20210220368A1 (en) 2021-07-22
AR108792A1 (es) 2018-09-26
AU2017285256A1 (en) 2019-01-24
JP2019518039A (ja) 2019-06-27
BR112018076014A2 (pt) 2019-03-26
CN109475561A (zh) 2019-03-15
EA201990041A1 (ru) 2019-05-31
EP3471731A1 (fr) 2019-04-24
WO2017216307A1 (fr) 2017-12-21
MX2018015240A (es) 2019-04-15
TW201803568A (zh) 2018-02-01
CA3026974A1 (fr) 2017-12-21
KR20190017801A (ko) 2019-02-20

Similar Documents

Publication Publication Date Title
EP3684353A4 (fr) Formulations topiques de cannabinoïdes et leur utilisation dans le traitement de la douleur
MX377340B (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
MA39960A (fr) Composés imidazo[4,5c]quinoline-2-one et leur utilisation dans le traitement du cancer
MA52257A (fr) Compositions pharmaceutiques comprenant blautia et leur administration orale
PL3383363T3 (pl) Preparaty farmaceutyczne do stosowania miejscowego do leczenia stanów związanych z zapaleniem
PL3896064T3 (pl) Pochodne 4,6-diamino-chinolino-3-karbonitrylu jako modulatory cot w leczeniu choroby leśniowskiego-crohna i wrzodziejącego zapalenia jelita grubego
IL255119B (en) Therapeutic pooled blood apoptotic cell preparations and uses thereof
BR112017015310A2 (pt) uso de pgr4 como um agente anti-inflamatório
WO2016004305A3 (fr) Inhibiteurs de la tyrosine kinase de bruton
MX2015009058A (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
HUE060496T2 (hu) Terápiás vegyületek és készítmények szociális zavarok és szerhasználati zavarok kezelésére
MX2015009045A (es) Composiciones y metodos para tratar el dolor severo.
SI3723739T1 (sl) Paraziticidni pripravki na osnovi izoksazolina in njihova uporaba za zdravljenje blefaritisa
MA46608A (fr) Formulation liposomale destinée à être utilisée dans le traitement du cancer
MA52644A (fr) Compositions pharmaceutiques comprenant de l'acide dgla et leur utilisation
EP3848022C0 (fr) Agent thérapeutique pour utilisation dans le traitement d'infections
IL287704A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
MA42915A (fr) Pyridines et leur utilisation dans le traitement du cancer
MA47450A (fr) Sulfinylpyridines et leur utilisation dans le traitement du cancer
EP3678692A4 (fr) Stratification du génotype dans le traitement et la prévention du diabète
MA49884A (fr) Composés imidazo[4,5-c]quinolin-2-one deutérés et leur utilisation dans le traitement du cancer
MA47451A (fr) Pyridines à substitution hétéroarylsulfonyle et leur utilisation dans le traitement du cancer
IL264407A (en) Novel application of gzd824 and pharmaceutically acceptable salts thereof in treating diseases
EP3302464A4 (fr) Utilisation de cannabinoïdes dans le traitement de l'inflammation et/ou de la douleur oculaire
EA201592242A1 (ru) Производные пиридона для лечения вирусных инфекций и других заболеваний